Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

PURPOSE: Accurate response assessment during neoadjuvant systemic treatment (NST) poses a clinical challenge. Therefore, a minimally invasive assessment of tumor response based on cell-free circulating tumor DNA (ctDNA) may be beneficial to guide treatment decisions. EXPERIMENTAL DESIGN: We profiled...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qing, Gampenrieder, Simon P., Frantal, Sophie, Rinnerthaler, Gabriel, Singer, Christian F., Egle, Daniel, Pfeiler, Georg, Bartsch, Rupert, Wette, Viktor, Pichler, Angelika, Petru, Edgar, Dubsky, Peter C., Bago-Horvath, Zsuzsanna, Fesl, Christian, Rudas, Margaretha, Ståhlberg, Anders, Graf, Ricarda, Weber, Sabrina, Dandachi, Nadia, Filipits, Martin, Gnant, Michael, Balic, Marija, Heitzer, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377752/
https://www.ncbi.nlm.nih.gov/pubmed/34862246
http://dx.doi.org/10.1158/1078-0432.CCR-21-3231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377752/
https://www.ncbi.nlm.nih.gov/pubmed/34862246
http://dx.doi.org/10.1158/1078-0432.CCR-21-3231

Ejemplares similares